American Pharmaceutical Partners Inc (Schaumburg, Ill) recently announced FDA approval to launch Piperacillin for Injection USP, the generic equivalent of Wyeth?s Pipracil. Piperacillin is a third-generation antibiotic indicated for the treatment of serious infections caused by designated susceptible microorganisms such as Pseudomonas aeruginosa. This antibiotic is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria. These microorganisms are found in a variety of conditions, including intra-abdominal infections, urinary tract infections, gynecologic infections, septicemia, lower respiratory tract infections, skin and skin-structure infections, bone and joint infections, and uncomplicated gonoccocal urethritis. For more information, visit www.appdrugs.com.
Although the annual HIV diagnosis rate between 2010 and 2014 decreased for black individuals by 16.2%, blacks remain disproportionately affected by HIV/AIDS.
Clinical features with downloadable PDFs